Pfizer Inc. (NYSE:PFE) Shares Sold by McIlrath & Eck LLC

McIlrath & Eck LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 11.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,510 shares of the biopharmaceutical company’s stock after selling 439 shares during the quarter. McIlrath & Eck LLC’s holdings in Pfizer were worth $126,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Nuveen Asset Management LLC raised its holdings in shares of Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after acquiring an additional 34,544,423 shares during the last quarter. Natixis acquired a new position in shares of Pfizer during the second quarter valued at approximately $258,466,000. Invesco Ltd. increased its holdings in shares of Pfizer by 14.6% in the second quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after purchasing an additional 2,693,349 shares during the last quarter. DNB Asset Management AS increased its holdings in shares of Pfizer by 241.0% in the third quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after purchasing an additional 2,638,873 shares during the last quarter. Finally, Thoroughbred Financial Services LLC increased its holdings in shares of Pfizer by 4,297.8% in the second quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after purchasing an additional 2,596,269 shares during the last quarter. 71.52% of the stock is owned by institutional investors and hedge funds.

In other Pfizer news, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Scott Gottlieb acquired 3,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Several research firms recently commented on PFE. Bank of America began coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a report on Wednesday, August 28th. Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 price target on shares of Pfizer in a report on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Nine research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $44.02.

Pfizer stock traded up $0.14 during mid-day trading on Friday, hitting $37.05. The company’s stock had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. The firm has a market capitalization of $207.30 billion, a PE ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The stock’s fifty day moving average is $36.62 and its two-hundred day moving average is $39.26.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The firm’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.78 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.89%. Pfizer’s payout ratio is 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Trading Penny Stocks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.